logo-loader
viewTRACON Pharmaceuticals

TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data presentation on May 31

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners will present positive data from a Phase 2 cancer trial of the drug envafolimab at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

Theuer says the trial enrolled 103 patients in China with high-mutation (MSI-H) colorectal (CRC) or gastric cancer (GC) or who had deficient Mismatch Repair (dMMR) in other solid tumors. dMMR prevents cells from repairing mistakes made during the division process.

Quick facts: TRACON Pharmaceuticals

Price: 1.66 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $14.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

TRACON Pharmaceuticals - Proactive One2One Virtual Event

TRACON Pharmaceuticals' (NASDAQ:TCON) Charles Theuer presents to investors at the Proactive One2One Virtual Conference. TRACON is a clinical state biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related muscular...

2 days, 12 hours ago

2 min read